These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 19153271

  • 1. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J.
    Circulation; 2009 Feb 03; 119(4):524-9. PubMed ID: 19153271
    [Abstract] [Full Text] [Related]

  • 2. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F, Pieroni M, Chimenti C, Frustaci A, Sarais C, Cecchi F, Area Cardiologica-Advisory Board Plan Multidisciplinare "Diagnosi e Follow-up Malattia di Fabry".
    G Ital Cardiol (Rome); 2010 Feb 03; 11(7-8):566-72. PubMed ID: 21033333
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
    Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E, Becker G.
    Intern Med J; 2008 Jun 03; 38(6):407-14. PubMed ID: 18613897
    [Abstract] [Full Text] [Related]

  • 5. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
    Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM.
    Eur Heart J; 2005 Jun 03; 26(12):1221-7. PubMed ID: 15728649
    [Abstract] [Full Text] [Related]

  • 6. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].
    Dumont CA, Monserrat L, Soler R, Rodríguez E, Fernández X, Peteiro J, Bouzas B, Piñón P, Castro-Beiras A.
    Rev Esp Cardiol; 2007 Jan 03; 60(1):15-23. PubMed ID: 17288951
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis.
    van Dockum WG, Kuijer JP, Götte MJ, Ten Cate FJ, Ten Berg JM, Beek AM, Twisk JW, Marcus JT, Visser CA, van Rossum AC.
    Eur Heart J; 2006 Dec 03; 27(23):2833-9. PubMed ID: 17098761
    [Abstract] [Full Text] [Related]

  • 11. Tei index in fabry disease.
    Niemann M, Breunig F, Beer M, Hu K, Liu D, Emmert A, Herrmann S, Ertl G, Wanner C, Takenaka T, Tei C, Weidemann F.
    J Am Soc Echocardiogr; 2011 Sep 03; 24(9):1026-32. PubMed ID: 21719255
    [Abstract] [Full Text] [Related]

  • 12. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW.
    Circulation; 2009 May 19; 119(19):2561-7. PubMed ID: 19414635
    [Abstract] [Full Text] [Related]

  • 13. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
    Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F.
    JACC Cardiovasc Imaging; 2011 Jun 19; 4(6):592-601. PubMed ID: 21679893
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
    Romero-Puche A, Marín F, González-Carrillo J, García-Honrubia A, Climent V, Feliu E, Ruiz-Espejo F, Payá E, Gimeno-Blanes JR, de la Morena G, Valdés-Chavarri M.
    Rev Esp Cardiol; 2008 Aug 19; 61(8):853-60. PubMed ID: 18684368
    [Abstract] [Full Text] [Related]

  • 16. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
    Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H.
    Z Kardiol; 2002 Dec 19; 91(12):992-1002. PubMed ID: 12490989
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.
    Krämer J, Niemann M, Liu D, Hu K, Machann W, Beer M, Wanner C, Ertl G, Weidemann F.
    Eur Heart J; 2013 Jun 19; 34(21):1587-96. PubMed ID: 23520186
    [Abstract] [Full Text] [Related]

  • 19. Use of quantitative analysis of remote myocardial fibrosis with delayed-enhancement magnetic resonance imaging to predict outcomes after surgical ventricular restoration for ischemic cardiomyopathy.
    Takeda K, Matsumiya G, Matsue H, Hamada S, Sakaki M, Sakaguchi T, Fujita T, Sawa Y.
    J Thorac Cardiovasc Surg; 2008 Dec 19; 136(6):1514-21. PubMed ID: 19114200
    [Abstract] [Full Text] [Related]

  • 20. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ, Banikazemi M.
    Nephrol Ther; 2006 Jan 19; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.